1. Effect of pre‐transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis
- Author
-
Jeffrey H. Lipton, Jonas Mattsson, Shiyi Chen, Auro Viswabandya, Maria Queralt Salas, Shruti Prem, Arjun Law, Fotios V. Michelis, Wilson Lam, Vikas Gupta, Sunu Cyriac, Rajat Kumar, Dennis Dong Hwan Kim, and Zeyad Al-Shaibani
- Subjects
Adult ,Male ,medicine.medical_specialty ,Graft failure ,Cd34 cells ,Dose-Response Relationship, Immunologic ,CD34 ,Graft vs Host Disease ,Antigens, CD34 ,Gastroenterology ,Relapse free survival ,Cell transplantation ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Transplantation, Homologous ,Medicine ,Cumulative incidence ,Myelofibrosis ,Protein Kinase Inhibitors ,Aged ,business.industry ,Hematopoietic Stem Cell Transplantation ,Janus Kinase 1 ,Hematology ,General Medicine ,Janus Kinase 2 ,Middle Aged ,medicine.disease ,Survival Analysis ,Treatment Outcome ,surgical procedures, operative ,Graft-versus-host disease ,Primary Myelofibrosis ,Female ,business - Abstract
Allogeneic hematopoeitic cell transplantation (allo-HCT) is the only curative treatment for myelofibrosis (MF). We evaluate the impact of various factors on survival outcomes post-transplant in MF. Data of 89 consecutive MF patients (primary 47%) who underwent allo-HCT between 2005 and 2018 was evaluated. Fifty-four percent patients had received JAK1/2 inhibitors (JAKi) pre-HCT. The median CD34 count was 7.1x106 cells/kg. Graft failure was seen in 10% of the patients. Grade 3-4 acute GVHD (aGVHD) and moderate/severe chronic graft versus host disease (cGVHD) occurred in 24% and 40% patients, respectively. Two-year overall survival (OS) and relapse free survival (RFS) were 51% and 43%, respectively. Cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) at 2 years were 11% and 46%, respectively. Higher CD34 cell dose (≤5 × 106 cells/kg vs 5-9 or ≥9 × 106 cells/kg) and lower pre-HCT ferritin (
- Published
- 2021
- Full Text
- View/download PDF